MX2017003464A - Inhibidores de histona desmetilasa. - Google Patents

Inhibidores de histona desmetilasa.

Info

Publication number
MX2017003464A
MX2017003464A MX2017003464A MX2017003464A MX2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A MX 2017003464 A MX2017003464 A MX 2017003464A
Authority
MX
Mexico
Prior art keywords
cancer
compositions
compounds
histone demethylase
useful
Prior art date
Application number
MX2017003464A
Other languages
English (en)
Inventor
Nie Zhe
Alan Stafford Jeffrey
Marvin Veal James
K Chen Young
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of MX2017003464A publication Critical patent/MX2017003464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona generalmente a composiciones y métodos para tratar cáncer y enfermedades neoplasticas. Se porporcionan en la presente compuestos derivados de imidazol-piridina sustituidos y composiciones farmacéuticas que comprense los compuestos. Los presentes compuestos y composiciones son útiles para la inhibición de enzimas de histonia desmetilasa. Además, los presentes compuestos y composiciones son útiles para el tratamiento de cáncer pancreático, cáncer de próstata, cáncer de seno, cáncer de vejiga, cáncer de pulmón, cáncer gástrico, leucemia y/o melanoma y los similares.
MX2017003464A 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa. MX2017003464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051268P 2014-09-16 2014-09-16
PCT/US2015/050289 WO2016044342A1 (en) 2014-09-16 2015-09-15 Histone demethylase inhibitors

Publications (1)

Publication Number Publication Date
MX2017003464A true MX2017003464A (es) 2017-07-13

Family

ID=55533770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003464A MX2017003464A (es) 2014-09-16 2015-09-15 Inhibidores de histona desmetilasa.

Country Status (17)

Country Link
US (2) US9676770B2 (es)
EP (1) EP3193881B1 (es)
JP (1) JP6660060B2 (es)
KR (1) KR20170048590A (es)
CN (1) CN107073006A (es)
AU (1) AU2015317904A1 (es)
BR (1) BR112017005128A2 (es)
CA (1) CA2961525A1 (es)
CL (1) CL2017000643A1 (es)
CO (1) CO2017002772A2 (es)
EA (1) EA201790502A1 (es)
EC (1) ECSP17020172A (es)
ES (1) ES2911292T3 (es)
IL (1) IL251103A0 (es)
MX (1) MX2017003464A (es)
SG (1) SG11201702108PA (es)
WO (1) WO2016044342A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6276378B2 (ja) 2013-03-14 2018-02-07 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9676770B2 (en) 2014-09-16 2017-06-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US20170190689A1 (en) * 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
EP3436445B1 (en) * 2016-03-15 2023-09-06 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JP7244504B2 (ja) 2017-10-18 2023-03-22 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
PT3847175T (pt) 2018-09-05 2024-04-16 Incyte Corp Formas cristalinas de um inibidor da fosfoinositídeo 3-quinase (pi3k)
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20090221589A1 (en) 2005-12-19 2009-09-03 Thomas Trieselmann Use of aminoalcohol derivatives for the treatment of overactive bladder
NZ584311A (en) 2007-10-03 2012-03-30 Vertex Pharma Phenyl and pyridyl substituted tetrazole c-met protein kinase inhibitors
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DK2499139T3 (da) 2009-11-10 2014-01-27 Pfizer N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere
AU2011205283B2 (en) 2010-01-13 2014-07-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2928471B1 (en) 2012-12-06 2020-10-14 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6276378B2 (ja) 2013-03-14 2018-02-07 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9896436B2 (en) * 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9676770B2 (en) 2014-09-16 2017-06-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
JP6660060B2 (ja) 2020-03-04
CO2017002772A2 (es) 2017-06-09
CN107073006A (zh) 2017-08-18
BR112017005128A2 (pt) 2018-07-31
JP2017527590A (ja) 2017-09-21
IL251103A0 (en) 2017-04-30
CA2961525A1 (en) 2016-03-24
SG11201702108PA (en) 2017-04-27
AU2015317904A1 (en) 2017-04-06
ECSP17020172A (es) 2017-05-31
US9676770B2 (en) 2017-06-13
EP3193881A1 (en) 2017-07-26
EP3193881A4 (en) 2018-02-21
US10071984B2 (en) 2018-09-11
US20160108033A1 (en) 2016-04-21
US20170240529A1 (en) 2017-08-24
EP3193881B1 (en) 2022-02-09
CL2017000643A1 (es) 2017-12-01
EA201790502A1 (ru) 2017-10-31
WO2016044342A1 (en) 2016-03-24
KR20170048590A (ko) 2017-05-08
ES2911292T3 (es) 2022-05-18

Similar Documents

Publication Publication Date Title
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
TW201613882A (en) Histone demethylase inhibitors
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX2017000170A (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX2017003466A (es) Inhibidores de histona desmetilasa.
MX2017003463A (es) Inhibidores de histona desmetilasa.